On August 22, 2018 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, reported that it will participate in two upcoming investor conferences (Press release, Halozyme, AUG 22, 2018, View Source [SID1234529026]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Helen Torley, president and chief executive officer of Halozyme, will participate in Citigroup’s 13th Annual Biotech Conference in Boston on Wednesday, September 5, 2018. Dr. Torley will represent Halozyme on a panel titled "Targeted Therapies Oncology – Aiming for the Bull’s Eye" at the conference.

On Thursday, September 6, 2018, Dr. Torley will present an overview of the company at the 2018 Wells Fargo Securities Healthcare Conference in Boston at 1:20 p.m. ET / 10:20 a.m. PT. A live audio webcast of the presentation will be available in the "Investors" section of Halozyme’s website at www.halozyme.com with an archived replay available for 90 days following the event.